Key result
In patients with multiple myeloma, LMWH significantly reduced symptomatic VTE compared with warfarin (RR 0.33; 95% CI 0.14-0.83), though routine prophylaxis requires further safety evaluation.
Why the study?
Does primary thromboprophylaxis reduce symptomatic VTE in ambulatory cancer patients receiving chemotherapy?
Population
Ambulatory cancer patients receiving chemotherapy
Comparison
Primary thromboprophylaxis vs Placebo, no thromboprophylaxis, or an…
Design
Systematic_review
Authors
Loading...
May support LMWH over warfarin for VTE prophylaxis in multiple myeloma; leaves open safety evaluation for routine use.
Systematic Review
Does primary thromboprophylaxis reduce symptomatic VTE in ambulatory cancer patients receiving chemotherapy?
Relative Risk: 0.33 (95% CI 0.14–0.83)
While primary thromboprophylaxis with LMWH reduces symptomatic VTE in ambulatory cancer patients on chemotherapy, routine use cannot be recommended until bleeding safety issues are adequately addressed.
Nisio et al. (2016) conducted a systematic review in Venous thromboembolism in ambulatory cancer patients. Primary thromboprophylaxis (e.g., LMWH, apixaban) vs. Placebo, no thromboprophylaxis, or other anticoagulants was evaluated on Symptomatic VTE (LMWH vs warfarin in multiple myeloma) (RR 0.33, 95% CI 0.14 to 0.83). In patients with multiple myeloma, LMWH significantly reduced symptomatic VTE compared with warfarin (RR 0.33; 95% CI 0.14-0.83), though routine prophylaxis requires further safety evaluation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: